All studies
Cardiology · EHR · US

Li 2026

Heart failure with reduced ejection fraction

ITTSuperiorityAcademia1/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
All-cause mortality
vs DAPA-HF·HR·Efficacy
0.830.71–0.97
1.680.83–3.41
overlapMajor deviation1.91 SE apart

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
Propensity-score matching
Analysis method
Cox proportional hazards model and Meta-S learner
Missing data
Not reported
DAG
No
QBA
No

Data and sample

Data type
EHR
Data sources
1
Geography
US
Eligible sample
9014
Treated
149
Control
8865
Emulations
1
Treatments compared
2

Transparency

1/5
Protocol
No pre-registration
Preprint
It's a preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Not declared
Funding
Declared: Public, Research institute
Funders
NIH NIGMS R00GM135488; NIH R01AG084236; Mayo Clinic Department Chair; Nancy Peretsman and Robert Scully Chair

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Li_DAPAHF
DOI
https://doi.org/10.48550/arxiv.2607.16934
Affiliations
Mayo Clinic; Virginia Commonwealth University
Sector
Academia
Target trials (study level)
DAPA-HF
Registration
NCT03036124